Cargando…
Enhanced Efficacy of Vaccination With Vaccinia Virus in Old vs. Young Mice
Immunosenescence is believed to be responsible for poor vaccine efficacy in the elderly. To overcome this difficulty, research into vaccination strategies and the mechanisms of immune responses to vaccination is required. By analyzing the innate and adaptive immune responses to vaccination with vacc...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685358/ https://www.ncbi.nlm.nih.gov/pubmed/31417558 http://dx.doi.org/10.3389/fimmu.2019.01780 |
_version_ | 1783442389698871296 |
---|---|
author | Shmeleva, Evgeniya V. Smith, Geoffrey L. Ferguson, Brian J. |
author_facet | Shmeleva, Evgeniya V. Smith, Geoffrey L. Ferguson, Brian J. |
author_sort | Shmeleva, Evgeniya V. |
collection | PubMed |
description | Immunosenescence is believed to be responsible for poor vaccine efficacy in the elderly. To overcome this difficulty, research into vaccination strategies and the mechanisms of immune responses to vaccination is required. By analyzing the innate and adaptive immune responses to vaccination with vaccinia virus (VACV) in mice of different age groups, we found that immune cell recruitment, production of cytokines/chemokines and control of viral replication at the site of intradermal vaccination were preserved in aged mice and were comparable with younger groups. Analysis of cervical draining lymph nodes (dLN) collected after vaccination showed that numbers of germinal center B cells and follicular T helper cells were similar across different age groups. The number of VACV-specific CD8 T cells in the spleen and the levels of serum neutralizing antibodies 1 month after vaccination were also comparable across all age groups. However, following intranasal challenge of vaccinated mice, body weight loss was lower and virus was cleared more rapidly in aged mice than in younger animals. In conclusion, vaccination with VACV can induce an effective immune response and stronger protection in elderly animals. Thus, the development of recombinant VACV-based vaccines against different infectious diseases should be considered as a strategy for improving vaccine immunogenicity and efficacy in the elderly. |
format | Online Article Text |
id | pubmed-6685358 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-66853582019-08-15 Enhanced Efficacy of Vaccination With Vaccinia Virus in Old vs. Young Mice Shmeleva, Evgeniya V. Smith, Geoffrey L. Ferguson, Brian J. Front Immunol Immunology Immunosenescence is believed to be responsible for poor vaccine efficacy in the elderly. To overcome this difficulty, research into vaccination strategies and the mechanisms of immune responses to vaccination is required. By analyzing the innate and adaptive immune responses to vaccination with vaccinia virus (VACV) in mice of different age groups, we found that immune cell recruitment, production of cytokines/chemokines and control of viral replication at the site of intradermal vaccination were preserved in aged mice and were comparable with younger groups. Analysis of cervical draining lymph nodes (dLN) collected after vaccination showed that numbers of germinal center B cells and follicular T helper cells were similar across different age groups. The number of VACV-specific CD8 T cells in the spleen and the levels of serum neutralizing antibodies 1 month after vaccination were also comparable across all age groups. However, following intranasal challenge of vaccinated mice, body weight loss was lower and virus was cleared more rapidly in aged mice than in younger animals. In conclusion, vaccination with VACV can induce an effective immune response and stronger protection in elderly animals. Thus, the development of recombinant VACV-based vaccines against different infectious diseases should be considered as a strategy for improving vaccine immunogenicity and efficacy in the elderly. Frontiers Media S.A. 2019-07-31 /pmc/articles/PMC6685358/ /pubmed/31417558 http://dx.doi.org/10.3389/fimmu.2019.01780 Text en Copyright © 2019 Shmeleva, Smith and Ferguson. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Shmeleva, Evgeniya V. Smith, Geoffrey L. Ferguson, Brian J. Enhanced Efficacy of Vaccination With Vaccinia Virus in Old vs. Young Mice |
title | Enhanced Efficacy of Vaccination With Vaccinia Virus in Old vs. Young Mice |
title_full | Enhanced Efficacy of Vaccination With Vaccinia Virus in Old vs. Young Mice |
title_fullStr | Enhanced Efficacy of Vaccination With Vaccinia Virus in Old vs. Young Mice |
title_full_unstemmed | Enhanced Efficacy of Vaccination With Vaccinia Virus in Old vs. Young Mice |
title_short | Enhanced Efficacy of Vaccination With Vaccinia Virus in Old vs. Young Mice |
title_sort | enhanced efficacy of vaccination with vaccinia virus in old vs. young mice |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685358/ https://www.ncbi.nlm.nih.gov/pubmed/31417558 http://dx.doi.org/10.3389/fimmu.2019.01780 |
work_keys_str_mv | AT shmelevaevgeniyav enhancedefficacyofvaccinationwithvacciniavirusinoldvsyoungmice AT smithgeoffreyl enhancedefficacyofvaccinationwithvacciniavirusinoldvsyoungmice AT fergusonbrianj enhancedefficacyofvaccinationwithvacciniavirusinoldvsyoungmice |